类药物降低了患有2型糖尿病的老年人 Delirium 风险
Mingyang Sun1, Xiaoling Wang2, Zhongyuan Lu2
1Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Journal of the American Medical Directors Association
|February 14, 2025
概括
类药物显著降低了患有2型糖尿病的老年人妄风险. 水友性他类药物和较高剂量提供了更大的保护,这表明它在预防认知能力下降方面发挥了作用.
科学领域:
- 老年学是指老年学的学科.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 患有2型糖尿病 (T2DM) 的老年人患狂妄症的风险增加.
- 类药物广泛用于降低心血管风险,但它们对T2DM痴呆症的影响尚未完全理解.
研究的目的:
- 研究他类药物对患有T2DM的老年人妄发病率的影响.
- 为了比较水友性与脂友性他类药物的疗效.
- 为了检查他类药物治疗的剂量反应关系.
主要方法:
- 使用台湾国家健康保险研究数据库 (2008-2021) 对110,090名患有T2DM的老年人进行了回顾性队列研究.
- 倾向性得分匹配被用来比较55 045名他类药物使用者和55 045名非使用者.
- 考克斯回归和竞争风险分析,经过调整以考虑混因素和死亡率.
主要成果:
- 达丁类药物使用与妄风险显著降低有关 (aHR,0.73;P < .0001).
- 水友性他类药物表现出比脂友性他类药物 (aHR,0.76) 更大的保护作用 (aHR,0.67).
- 较高的累积他类药物剂量与较大的风险降低相关,最高四分位数显示实质性益处 (aHR,0.36).
结论:
- 类药物,特别是高剂量的类药物,在患有T2DM的老年人中显著降低了妄想发作的发生率.
- 这些发现支持在这个人群中使用他类药物进行认知保护.
- 结果对临床实践有意义,并突出了他类药物在治疗T2DM相关并发症方面的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
512
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
512
Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
Psychoneuroimmunology: Diabetes and Cancer
21
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
21
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150


